BCM
TBRA

Blume Capital Management’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Blume Capital Management’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,400
Closed -$33K – 265
2015
Q3 		$33K Hold
3,400
– – 0.03% 124
2015
Q2 		$59K Buy
+3,400
New +$49.7K 0.04% 99

Other funds holding TBRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Blume Capital Management's TBRA Position: Q4 2015 in Review

Blume Capital Management sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2015, closing a stake of 3,400 shares — an estimated $33K sold.

Blume Capital Management first reported a position in TBRA in Q2 2015 and held it in 2 quarters. The position peaked at $59K in Q2 2015. 48 funds tracked by Wall St. Rank hold TBRA as of Q4 2015.

  • Blume Capital Management reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Blume Capital Management sold 3,400 Tobira Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $33K.
  • Blume Capital Management first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Blume Capital Management's Tobira Therapeutics, Inc. Common Stock position peaked at $59K in Q2 2015.
  • 48 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Blume Capital Management's 13F filing for Q4 2015, filed 8 Feb 2016.